About Index Trending news
Analyze
Pricing
Novartis Venture Fund

Novartis Venture Fund

Novartis Venture Fund

I work here Suggest edits
More info

Elsewhere

Alexa global traffic share

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Investments 45

Portfolio

Portfolio tracker
Add info

Investment profile

Target markets
Health Care Biotechnology Health Diagnostics

Activity

Past year's investments

- Novartis Venture Fund participated in 9 rounds in the past year.
- The total disclosed amount of capital deployed in those rounds was $292,982,051 (averaging $32,553,561 per round).

Latest rounds

- Effector Therapeutics: Venture capital (Series C) ($38.6M)
- NeuroVia: Venture capital (Series A) ($14M)
- Neurovia: Venture capital (Series A) ($14M)

Main Co-investors

- Morgenthaler Ventures
- Consort Medical
- SR One

BioNano Genomics

BioNano Genomics

Maps +1
Total funding
$102.1M in 6 rounds from 13 investors
By Novartis Venture Fund
$53M Series C in Nov, 2014
Atlas Genetics

Atlas Genetics

Biotechnology +1
Total funding
$110.4M in 4 rounds from 25 investors
By Novartis Venture Fund
$35M Series D in Jan, 2017
Altimmune

Altimmune

Health Care +1
Total funding
$30.7M in 2 rounds from 5 investors
By Novartis Venture Fund
$16M Venture capital in Feb, 2015
Merganser Biotech, Inc.

Merganser Biotech, Inc.

Biotechnology
Total funding
$28M in 1 rounds from 5 investors
By Novartis Venture Fund
$28M Series A in Feb, 2015
Pulmatrix

Pulmatrix

Biotechnology
Total funding
$43.7M in 3 rounds from 11 investors
By Novartis Venture Fund
$30.2M Series B in Nov, 2009
Seventh Sense Biosystems

Seventh Sense Biosystems

Biotechnology
Total funding
$41.8M in 6 rounds from 13 investors
By Novartis Venture Fund
$16M Series B in Aug, 2014
Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc.

Biotechnology
Total funding
$73.6M in 2 rounds from 6 investors
By Novartis Venture Fund
$70.6M Series A in Aug, 2008
Alios BioPharma

Alios BioPharma

Biotechnology
Total funding
$49M in 2 rounds from 7 investors
By Novartis Venture Fund
$41M Series B in Apr, 2014
NovImmune

NovImmune

Biotechnology
Total funding
$137.2M in 4 rounds from 15 investors
By Novartis Venture Fund
$54.8M Series C in May, 2009
Catalyst Biosciences

Catalyst Biosciences

Biotechnology
Total funding
$96.7M in 6 rounds from 26 investors
By Novartis Venture Fund
$5.1M Venture capital in Apr, 2013
Effector Therapeutics

Effector Therapeutics

Biotechnology
Total funding
$83.6M in 2 rounds from 19 investors
By Novartis Venture Fund
$38.6M Series C in Jul, 2017
Akebia Therapeutics

Akebia Therapeutics

Health Care +1
Total funding
$61.1M in 3 rounds from 21 investors
By Novartis Venture Fund
$41M Series C in Jun, 2013
Trellis Bioscience

Trellis Bioscience

Biotechnology
Total funding
$10M in 1 rounds from 4 investors
By Novartis Venture Fund
$10M Series B in Feb, 2007
Visiogen

Visiogen

Health Care
Total funding
$40M in 1 rounds from 7 investors
By Novartis Venture Fund
$40M Series D in May, 2009
Exit Abbott, Sep 3, 2009
Immune Targeting Systems

Immune Targeting Systems

Biotechnology
Total funding
$13.2M in 1 rounds from 4 investors
By Novartis Venture Fund
$13.2M Series A in Mar, 2010
Exit Altimmune, Feb 17, 2015
Advanced Animal Diagnostics

Advanced Animal Diagnostics

Biotechnology
Total funding
$27.7M in 3 rounds from 5 investors
By Novartis Venture Fund
$11M Series B in Mar, 2011
ImaginAb

ImaginAb

Biotechnology +1
Total funding
$46.8M in 4 rounds from 13 investors
By Novartis Venture Fund
$21M Series B in May, 2014
ROX Medical

ROX Medical

Health Care
Total funding
$46M in 2 rounds from 6 investors
By Novartis Venture Fund
$40M Series E in Sep, 2016
FORMA Therapeutics

FORMA Therapeutics

Biotechnology
Total funding
$29.5M in 2 rounds from 4 investors
By Novartis Venture Fund
$25.5M Series B in Dec, 2009
Quartet Medicine

Quartet Medicine

Biotechnology
Total funding
$17M in 1 rounds from 3 investors
By Novartis Venture Fund
$17M Series A in Oct, 2014
Aerie Pharmaceuticals

Aerie Pharmaceuticals

Biotechnology +1
Total funding
$331.4M in 4 rounds from 9 investors
By Novartis Venture Fund
$40M Undisclosed in Mar, 2017
Adicet Bio

Adicet Bio

Biotechnology
Total funding
$51M in 1 rounds from 3 investors
By Novartis Venture Fund
$51M Series A in Jan, 2016
F2G

F2G

Medical +2
Total funding
$60M in 1 rounds from 8 investors
By Novartis Venture Fund
$60M Venture Capital in Jun, 2016
Annexon Biosciences

Annexon Biosciences

Biotechnology +2
Total funding
$44M in 1 rounds from 5 investors
By Novartis Venture Fund
$44M Series B in Jun, 2016
Lemonaid Health

Lemonaid Health

Mobile +1
Total funding
$12.7M in 2 rounds from 8 investors
By Novartis Venture Fund
$11M Series A in May, 2017
Cavion

Cavion

Health Care +1
Total funding
$31.1M in 3 rounds from 5 investors
By Novartis Venture Fund
$26.1M Series A in Jan, 2017
Bicycle Therapeutics

Bicycle Therapeutics

Biotechnology
Total funding
$89.3M in 3 rounds from 9 investors
By Novartis Venture Fund
£40M Series B in Jun, 2017
Neurovia

Neurovia

Biotechnology
Total funding
$14M in 1 rounds from 4 investors
By Novartis Venture Fund
$14M Series A in Jul, 2017
E-Scape Bio

E-Scape Bio

Health Care +1
Total funding
$63M in 1 rounds from 6 investors
By Novartis Venture Fund
$63M Series A in Jul, 2017
NeuroVia

NeuroVia

Biotechnology
Total funding
$14M in 1 rounds from 4 investors
By Novartis Venture Fund
$14M Series A in Jul, 2017

Want to see the complete list?
Go Pro!